Skye Bioscience names Puneet Arora, MD as Chief Medical Officer

Skye Bioscience announced the appointment of Puneet S. Arora, MD, MS, FACE, as Chief Medical Officer CMO. “We are thrilled to welcome Dr. Puneet Arora as the Chief Medical Officer at Skye at this pivotal moment in our journey, particularly with the initiation of the Phase 2 CBeyond(TM) obesity clinical trial for nimacimab, our differentiated CB1 inhibitor,” said Punit Dhillon, Skye’s CEO and Chair. “Dr. Arora is well-regarded in the industry, brings extensive experience in designing and executing clinical trials across multiple therapeutic areas, and has significant expertise in metabolic diseases such as obesity. Our purpose is to advance treatments that can significantly improve health outcomes and we look forward to leveraging his medical knowledge and deep understanding of regulatory and clinical development strategies in the metabolic field as we work toward that goal.”